TY - JOUR
T1 - Update on Blood Pressure Control and Renal Outcomes in Diabetes Mellitus
AU - Joven, Mark Henry
AU - Anderson, Robert J.
N1 - Publisher Copyright:
© 2015, Springer Science+Business Media New York.
Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2015/7/26
Y1 - 2015/7/26
N2 - Diabetic nephropathy (DN) is associated with a high incidence of cardiovascular (CV) morbidity and mortality. Although relationships between hypertension and diabetic nephropathy are complex, blood pressure (BP) control is an important management strategy in the prevention of onset and progression of DN in patients with diabetes mellitus (DM). Recent guidelines recommend less stringent BP targets among patients with type 2 DM and chronic kidney disease. These recommendations are based mostly on lack of benefit in CV outcomes with a low BP target. We review the current information on efficacy of BP control in improving renal outcomes in patients with type 2 DM. Presently, although intensive BP control has been was beneficial in decreasing albuminuria, it has not translated into reductions in risks of hard renal endpoints, such as progression to end-stage renal disease, the need for renal replacement therapy, and mortality from renal causes.
AB - Diabetic nephropathy (DN) is associated with a high incidence of cardiovascular (CV) morbidity and mortality. Although relationships between hypertension and diabetic nephropathy are complex, blood pressure (BP) control is an important management strategy in the prevention of onset and progression of DN in patients with diabetes mellitus (DM). Recent guidelines recommend less stringent BP targets among patients with type 2 DM and chronic kidney disease. These recommendations are based mostly on lack of benefit in CV outcomes with a low BP target. We review the current information on efficacy of BP control in improving renal outcomes in patients with type 2 DM. Presently, although intensive BP control has been was beneficial in decreasing albuminuria, it has not translated into reductions in risks of hard renal endpoints, such as progression to end-stage renal disease, the need for renal replacement therapy, and mortality from renal causes.
UR - http://www.scopus.com/inward/record.url?scp=84930202185&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930202185&partnerID=8YFLogxK
U2 - 10.1007/s11892-015-0613-6
DO - 10.1007/s11892-015-0613-6
M3 - Review article
C2 - 25990743
AN - SCOPUS:84930202185
VL - 15
JO - Current Diabetes Reports
JF - Current Diabetes Reports
SN - 1534-4827
IS - 7
M1 - 44
ER -